Fisher Asset Management LLC increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 137.9% during the third quarter, Holdings Channel reports. The institutional investor owned 196,199 shares of the company’s stock after acquiring an additional 113,723 shares during the period. Fisher Asset Management LLC’s holdings in Mirum Pharmaceuticals were worth $16,771,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in MIRM. Jupiter Topco LLC purchased a new position in Mirum Pharmaceuticals in the second quarter valued at about $691,672,000. Janus Henderson Group PLC lifted its position in shares of Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after acquiring an additional 880,505 shares during the period. BlackRock Inc. acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter valued at approximately $513,945,000. ABS Investment Management LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $245,847,000. Finally, William Blair Investment Management LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $164,453,000.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on MIRM shares. Royal Bank Of Canada restated an “outperform” rating and issued a $155.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. Stifel Nicolaus raised their price objective on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Weiss Ratings cut Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $137.00 to $152.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Finally, Cantor Fitzgerald boosted their target price on Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $155.56.
View Our Latest Analysis on Mirum Pharmaceuticals
Mirum Pharmaceuticals Price Performance
Shares of NASDAQ MIRM opened at $93.99 on Monday. The company has a current ratio of 2.07, a quick ratio of 1.98 and a debt-to-equity ratio of 1.28. The company’s 50-day moving average price is $88.79 and its 200 day moving average price is $98.41. Mirum Pharmaceuticals, Inc. has a 52 week low of $63.23 and a 52 week high of $130.00. The stock has a market cap of $6.14 billion, a price-to-earnings ratio of -6.08 and a beta of 0.75.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.38). The business had revenue of $185.72 million for the quarter, compared to analyst estimates of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The business’s revenue was up 39.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.05 EPS. As a group, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.47 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Laura Brege sold 14,167 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the completion of the transaction, the director directly owned 15,703 shares of the company’s stock, valued at $1,479,379.63. This trade represents a 47.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jolanda Howe sold 658 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president owned 616 shares of the company’s stock, valued at $61,600. This represents a 51.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 104,825 shares of company stock worth $10,160,873 over the last ninety days. 8.32% of the stock is currently owned by insiders.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
Read More
- Five stocks we like better than Mirum Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report).
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
